Dyax Corp.  

(Public, NASDAQ:DYAX)   Watch this stock  
Find more results for DYAX
25.07
+0.34 (1.37%)
Jul 28 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 24.46 - 26.12
52 week 8.44 - 30.55
Open 25.12
Vol / Avg. 0.00/958,157.00
Mkt cap 3.60B
P/E     -
Div/yield     -
EPS -0.10
Shares 145.67M
Beta 0.76
Inst. own 99%
Jul 29, 2015
Q2 2015 Dyax Corp Earnings Call - 5:00PM EDT - Add to calendar
Jul 29, 2015
Q2 2015 Dyax Corp Earnings Release Add to calendar
Jun 1, 2015
Dyax Corp at Jefferies Global Healthcare Conference
May 19, 2015
Dyax Corp Annual Shareholders Meeting
May 13, 2015
Dyax Corp at Bank of America Merrill Lynch Health Care Conference
May 6, 2015
Dyax Corp at Deutsche Bank Health Care Conference
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin -35.61% -14.53%
Operating margin -22.76% -1.51%
EBITD margin - -0.45%
Return on average assets -13.61% -6.76%
Return on average equity -28.09% -17.98%
Employees 124 -
CDP Score - -

Address

55 Network Dr
BURLINGTON, MA 01803-2756
United States - Map
+1-617-2505769 (Phone)
+1-617-2252501 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Dyax Corp is a biopharmaceutical company. The Company is focused on Hereditary Angioedema (HAE) and other Plasma-Kallikrein-Mediated (PKM) Disorders, and licensing and funded research portfolio. The Company develops and commercializes treatments for hereditary angioedema. The Company discovered and developed KALBITOR, a plasma kallikrein inhibitor, and is selling it in the United States for the treatment of acute attacks of HAE. Additionally, it discovered and is developing DX-2930, a human monoclonal antibody inhibitor of plasma kallikrein. It also developed a biomarker assay that detects the activation of plasma kallikrein in patient blood. The Company has a portfolio of product candidates being developed by licensees using its phage display technology. This portfolio includes one approved product, CYRAMZA (ramucirumab), which is marketed by Eli Lilly and Company (Lilly), and multiple product candidates in various stages of clinical development.

Officers and directors

Henry E. Blair Chairman of the Board
Age: 71
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Gustav A. Christensen President, Chief Executive Officer, Director
Age: 67
Bio & Compensation  - Reuters
George V. Migausky Chief Financial Officer, Executive Vice President
Age: 60
Bio & Compensation  - Reuters
Andrew D. Ashe Executive Vice President, General Counsel
Age: 48
Bio & Compensation  - Reuters
Burt A. Adelman M.D. Chief Medical Officer, Executive Vice President - Research and Development
Age: 62
Bio & Compensation  - Reuters
Todd Bazemore Executive Vice President and Chief Commercial Officer
Age: 44
Bio & Compensation  - Reuters
Mary Ann Gray Ph.D. Lead Independent Director
Age: 62
Bio & Compensation  - Reuters
Abbie C. Celniker Ph.D Independent Director
Age: 56
Bio & Compensation  - Reuters
Ron Cohen M.D. Independent Director
Age: 59
Bio & Compensation  - Reuters
James W. Fordyce Independent Director
Age: 72
Bio & Compensation  - Reuters